Találati lista | Tudóstér

001-es BibID:	BIBFORM132948
035-os BibID:	(scopus)105011883480 (wos)001538131900001
Első szerző:	Cortese, Marianna
Cím:	Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression / Cortese Marianna, Peng Xiaojing, Edan Gilles, Freedman Mark S., Hartung Hans-Peter, Montalban Xavier, Sandbrink Rupert, Radü Ernst-Wilhelm, Barkhof Frederik, Wicklein Eva-Maria, Kappos Ludwig, Ascherio Alberto, Bjornevik Kjetil, BENEFIT Study Group
Dátum:	2025
ISSN:	0028-3878 1526-632X
Megjegyzések:	Background and Objectives Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. Methods This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. Results We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39?0.95) and 0.60 (95% CI 0.37?0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38?0.94) and 0.65 (95% CI 0.43?0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. Discusssion Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Neurology. - 105 : 3 (2025), p. 1-11. -
További szerzők:	Peng, Xiaojing Edan, Gilles Freedman, Mark S. Hartung, Hans-Peter Montalbán, Xavier Sandbrink, Rupert Radü, Ernst-Wilhelm Barkhof, Frederik Wicklein, Eva-Maria Kappos, Ludwig Ascherio, Alberto Bjornevik, Kjetil Csépány Tünde (1956-) (neurológus, pszichiáter) Csiba László (1952-) (neurológus, pszichiáter) BENEFIT Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM067748
Első szerző:	Kappos, Ludwig
Cím:	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial / Ludwig Kappos, Gilles Edan, Mark S. Freedman, Xavier Montalbán, Hans-Peter Hartung, Bernhard Hemmer, Edward J. Fox, Frederik Barkhof, Sven Schippling, Andrea Schulze, Dirk Pleimes, Christoph Pohl, Rupert Sandbrink, Gustavo Suarez, Eva-Maria Wicklein, BENEFIT Study Group
Dátum:	2016
ISSN:	0028-3878
Megjegyzések:	Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay.Methods: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment. Eleven years after randomization, patients were reassessed.Results: Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible atparticipating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk of CDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (p 50.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931 [253, 3,296]; p50.0005) and lower overall annualized relapse rate (0.21 vs 0.26; p50.0018). Only25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiple sclerosis. Expanded Disability Status Scale scores remained low and stable, with no differencebetween treatment arms (median [Q1,Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better Paced Auditory Serial Addition Task?3 total scores (p 5 0.0070). Employment rates remained high, and health resource utilization tended to be low in both groups.MRI metrics did not differ between groups.Conclusions: Although the delay in treatment was relatively short, several clinical outcomes favored earlier treatment. Along with low rates of disability and disease progression in bothgroups, this supports the value of treatment at CIS.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Neurology 87 : 10 (2016), p. 978-987. -
További szerzők:	Edan, Gilles Freedman, Mark S. Montalbán, Xavier Hartung, Hans-Peter Hemmer, Bernhard Fox, Edward J. Barkhof, Frederik Schippling, Sven Schulze, Andrea Pleimes, Dirk Pohl, Christoph Sandbrink, Rupert Suarez, Gustavo Wicklein, Eva-Maria Csiba László (1952-) (neurológus, pszichiáter) Csépány Tünde (1956-) (neurológus, pszichiáter) BENEFIT Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM069440
Első szerző:	Lublin, Fred
Cím:	Oral fingolimod in primary progressive multiple sclerosis (INFORMS) : a phase 3, randomised, double-blind, placebo-controlled trial / Lublin Fred, Miller David H., Freedman Mark S., Cree Bruce A. C., Wolinsky Jerry S., Weiner Howard, Lubetzki Catherine, Hartung Hans-Peter, Montalban Xavier, Uitdehaag Bernard M. J., Merschhemke Martin, Li Bingbing, Putzki Norman, Liu Fonda C., Häring Dieter A., Kappos Ludwig, INFORMS study investigators
Dátum:	2016
ISSN:	0140-6736
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Lancet 387 : 10023 (2016), p. 1075-1084. -
További szerzők:	Miller, David H. Freedman, Mark S. Cree, Bruce A. C. Wolinsky, Jerry S. Weiner, Howard Lubetzki, Catherine Hartung, Hans-Peter Montalbán, Xavier Uitdehaag, Bernard M. J. Merschhemke, Martin Li, Bingbing Putzki, Norman Liu, Fonda C. Häring, Dieter A. Kappos, Ludwig Csiba László (1952-) (neurológus, pszichiáter) INFORMS study investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: